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Objective: To evaluate the utility of N terminal pro brain natriuretic peptide (NT-proBNP) as a diagnostic
marker for diastolic dysfunction or failure, systolic dysfunction, and significant valve disorders in patients
over 75 years.
Design: Cohort study.
Setting: Outpatient echocardiography service in a district general hospital.
Participants: 100 consecutive patients.
Main outcome measures: Sensitivity, specificity, positive predictive values, negative predictive values, and
area under receiver operating characteristic curve for NT-proBNP assay in the diagnosis of left ventricular
diastolic dysfunction or failure, systolic dysfunction, and significant valve disorders.
Results: For diagnosis of systolic dysfunction NT-proBNP level of 424 pg/ml had a sensitivity of 96%,
specificity of 45%, positive predictive value of 36%, and negative predictive value of 96%. The area under
the curve was 0.71 (95% confidence intervals: 0.69 to 0.89). In valve heart disease, level of 227 pg/ml
had sensitivity of 91%, specificity of 43%, positive predictive value of 40%, and negative predictive value of
92%. Patients with diastolic dysfunction/failure had lower plasma concentrations.
Conclusions: This study showed that NT-proBNP had excellent negative predictive value for systolic
dysfunction and significant valve disorders in very elderly patients. It increased significantly in systolic
dysfunction, valve heart disease, and atrial fibrillation. NT-proBNP is not useful in the diagnosis of diastolic
dysfunction or diastolic heart failure using standard echocardiography criteria.
H
eart failure is a clinical syndrome most commonly
encountered in the very elderly,1 but this group is least
represented in clinical trials.
Heart failure could result from systolic or diastolic
dysfunction. Diastolic dysfunction is defined as an abnorm-
ality of diastolic distensibility, filling, or relaxation of the left
ventricle. At least one third of all patients with congestive
cardiac failure have a normal or near normal ejection fraction
but in over 75 years of age this may be up to three quarters of
all patients.
Clinical diagnosis of heart failure is unreliable.
Echocardiogram is used as the diagnostic gold standard but
its availability is limited. N terminal pro brain natriuretic
peptide (NT-proBNP) is emerging as a diagnostic tool in the
diagnosis of heart failure. It increases with ventricular
volume expansion and pressure overload. It is raised in
several cardiac conditions but most studies have focused
predominantly on systolic dysfunction in comparatively
young patients.2–4
Controversies surround the diagnosis of diastolic dysfunc-
tion. Left ventricular (LV) diastolic parameters change with
ageing and the echocardiographic diagnosis of diastolic
dysfunction becomes complex. Hence it is imperative to
determine the diagnostic role of NT-proBNP in diastolic
dysfunction/failure in the elderly. However, there is only
limited information regarding its use in patients over 75
years.
The aim of this study was to evaluate the utility of NT-
proBNP as a diagnostic marker for diastolic dysfunction or
failure, systolic dysfunction, and significant valve disorders in
patients over 75 years of age.
METHODS
The study was approved by the local ethics committee. A
sample of 104 consecutive patients referred for echocardio-
graphy were invited to participate. All patients had a clinical
diagnosis of either cardiac failure or valve heart disease by a
general practitioner or a hospital physician. Exclusion criteria
included patients who could not give consent or declined to
participate in the study. Information on cardiac symptoms,
medical history, and drug treatment were obtained. Signs for
cardiac failure were recorded. Electrocardiogram and poster-
oanterior chest radiography were performed. Echocardiogram
including M-mode, 2D imaging, spectral, and colour flow
Doppler was performed by a single clinician or by a senior
echo technician. Echocardiograms performed by the echo
technician were reviewed by the same clinician. LV systolic
and diastolic volumes and ejection fraction were derived from
standard and modified Simpson’s method. Regional wall
motion abnormalities were recorded. Left atrial (LA) and LV
dimensions were measured from M-mode images according
to standard criteria. Transmitral pulsed Doppler velocity
recordings from three consecutive cardiac cycles were used to
derive measurements as follows: E and A velocities were the
peak values reached in early diastole and after atrial
contraction respectively. If the E/A ratio was normal, valsalva
manoeuvre was performed to look for pseudonormal pattern.
Deceleration time (DT) was the interval from the E wave
peak to the decline of the velocity to baseline. If there was no
return to baseline, extrapolation of the deceleration signal
was performed. Maximum pulmonary venous systolic (S)
and diastolic (D) flow velocities were obtained. Finally the
isovolumetric relaxation time (IVRT), the time in millise-
conds from the end of ejection to the onset of LV filling, was
obtained. In patients with AF, DT, IVRT, S and D flow
velocities were obtained and the average of the three readings
were considered.
Abbreviations: NT-proBNP, N terminal pro brain natriuretic peptide;
AUC, area under curve; LV, left ventricular; LA, left atrial; DT,
deceleration time; IVRT, isovolumetric relaxation time; ROC, receiver
operating characteristic curve
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Systolic dysfunction was defined as left ventricular ejection
fraction (LVEF) ,50%. Diastolic dysfunction was defined as
normal LVEF.50% and evidence of abnormal left ventricular
relaxation (IVRT .105 ms) and/or slow early left ventricular
filling (E/A ratio,0.5 and DT.280 ms) and/or S/D.2.5.
Diastolic heart failure was defined as the presence of
symptoms and signs of congestive cardiac failure and
diastolic dysfunction on echocardiogram. Patients were
categorised as having significant valve disease if there was
evidence of valve stenosis or more than mild regurgitation.
Plasma concentration of NT-proBNP was measured (Roche
Diagnostics) after echocardiography. This assay has a wide
range, is free from common interferences, is stable at room
temperature, and does not cross react with BNP. The test is
fully automated and accommodates testing of large numbers
of samples.5
Statistical analysis
The usefulness of the NT-proBNP in various groups was
assessed by plotting receiver operating characteristic curves
(ROC) with sensitivity on the y axis and 12specificity on the
x axis for various cut off values. The characteristics of the
ROC curves were used to determine cut off points for NT-
proBNP permitting examination of the sensitivity, specificity,
negative, and positive predictive values of NT-proBNP in each
case. ROC curves were used to examine the diagnostic utility
of NT-proBNP for several conditions including systolic
dysfunction, diastolic dysfunction, diastolic dysfunction with
LA enlargement, and left ventricular hypertrophy (LVH),
diastolic failure, significant valve heart disease, and atrial
fibrillation. NT-proBNP values were compared for each group
with and without the respective diagnosis. As the distribution
of NT-proBNP values was highly positively skewed, they were
log transformed and the geometric mean with 95% con-
fidence intervals was reported. Similarly comparisons
between groups using t tests were conducted on the log
transformed values of NT-proBNP.
NT-proBNP values are known to be raised in patients with
systolic failure and with valve heart disease.6 7 Hence to
evaluate the utility of NT-proBNP in diastolic dysfunction
and diastolic failure, patients with systolic dysfunction and
valve heart disease were excluded from analysis. Thereafter,
patients were divided into groups with either (a) presence or
absence of diastolic dysfunction (b) presence or absence of
diastolic failure (c) presence or absence of diastolic dysfunc-
tion with LA enlargement and LVH. To evaluate patients with
valve heart disease, patients with systolic dysfunction were
excluded and the remaining patients were categorised into
those with and without significant valve heart disease.
RESULTS
In total 100 patients were included in the study and their
characteristics are shown in table 1. Four patients were
excluded in line with the exclusion criteria.
Systolic dysfunction
Table 2 gives the NT-proBNP for the groups of patients with
and without systolic dysfunction. The geometric mean for the
Table 1 Characteristics of all patients
Demographic data:
Sex
Male/female (n) 40/60
Age (y)
Mean 82.4
Range 75–94
Symptoms and signs (%)
Shortness of breath 77
Paroxysmal nocturnal dyspnoea 6
Orthopnoea 21
Pedal oedema 58
Raised JVP 16
Lung crepitations 34
Comorbidity (%)
Hypertension 35
Diabetes mellitus 10
Ischaemic heart disease 38
Atrial fibrillation 35
Drug treatment (%)
Loop and thiazide diuretics 58
b blockers 33
ACE inhibitors/angiotensin II blockers 42
Spironolactone 4
Digoxin 22
Echocardiographic diagnosis (n)
Systolic dysfunction 25
Diastolic dysfunction* 26
Diastolic dysfunction with LAE and LVH* 8
Diastolic failure* 13
Valve heart disease* 22
*In the absence of systolic dysfunction.
Table 2 Characteristic NT-proBNP (pg/ml)
concentrations for patients with and without systolic
dysfunction
Systolic dysfunction Yes No
Number 25 75
Geometric mean 3227.8 507.6
95% CI 1642.1 to 6344.5 335.0 to 749.2
1.00
0.75
0.50
0.25
0.00
1.00
1 – Specificity
NT
proBNP
cut off
(pg/ml)
424
Sensitivity Specificity PPV NPV
96 45 36 97
1226 68 68 41 86
1689 60 76 45 85
6180 44 96 79 84
Se
ns
iti
vi
ty
0.00 0.25 0.50 0.75
Figure 1 The predictive utility of NT-proBNP for systolic dysfunction
evaluated using an ROC analysis comparing sensitivity to specificity
(above). Below the curve sensitivity, specificity, positive, and negative
predictive value (PPV and NPV) of NT-proBNP (pg/ml) at four cut off
values.
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group with systolic dysfunction was higher and the differ-
ence was significant (t (98) = 4.8, p,0.001).
The diagnostic utility of NT-proBNP for systolic dysfunc-
tion was evaluated using an ROC analysis (fig 1). The AUC
was 0.71 (95% confidence limits from 0.69 to 0.89). The
sensitivity, specificity, positive, and negative predictive values
at four cut off levels for NT-proBNP are also shown.
Diastolic dysfunction
Table 3 compares the geometric mean values of NT-proBNP
(pg/ml) for patients with and without diastolic dysfunction,
diastolic dysfunction with LA enlargement (LAE) and LVH,
and diastolic failure. The group diagnosed with diastolic
dysfunction had lower plasma NT-proBNP than the group
without diastolic dysfunction. The difference between the
two groups was significant (t (51) = 2.6, p = 0.01). Despite
the stricter diagnostic criterion in the other categories
patients without abnormal heart function had high NT-
proBNP (pg/ml) and hence the ROC analyses for these
diagnostic groups were not presented.
Atrial fibrillation
After excluding patients with systolic dysfunction, patients
with atrial fibrillation showed higher concentrations of NT-
proBNP (pg/ml) (t (51) = 3.2, p = 0.01) (table 4).
Valve heart disease
After excluding patients with systolic dysfunction, patients
with significant valve heart disease showed higher concen-
trations of NT-proBNP (pg/ml) and the difference was
significant (t (73) = 3.0, p = 0.004) (table 5).
The sensitivity, specificity, positive, and negative predictive
values at three cut off levels for NT-proBNP are also shown
(table 6).
In the case of left ventricular hypertrophy, the difference in
NT-pro BNP for those with and without LVH was not
significant (t (41),1).
The expected 97.5 centile values quoted by manufacturers
of the assay for subjects aged between 50 and 65 years are
,334 pg/ml for women and ,227 pg/ml for men. NT pro
BNP and BNP are known to increase with age but normal
values are yet to be determined. Extrapolating the values to
the over 75 age group, only 18 of 60 women and 10 of 40 men
had values less than 334 and 227 respectively. Of 28 patients,
one had evidence of systolic dysfunction, two had significant
valve disorders. McDonagh et al8 has quoted 123 pg/ml and
67 pg/ml as 95th centile values for this age group in normal
women and men respectively. Eleven women and four men
had values less these values; of 15, one had systolic
dysfunction and none had significant valve disorder.
DISCUSSION
This study investigated the utility of NT-proBNP in a cohort
of very elderly patients with suspected cardiac disorders
referred for echocardiography. Hence, NT-proBNP values
were generally high.
The results reinforced the usefulness of NT-proBNP in
patients with systolic dysfunction. Utility of NT-proBNP in
the diagnosis of systolic heart failure is well established in
community based studies. This study confirms its negative
predictive value in systolic dysfunction in secondary care
setting in the very elderly. Although values of NT-proBNP
were significantly higher in the systolic dysfunction group,
many subjects without systolic dysfunction had high NT-
proBNP thus reducing its specificity.
In our study, NT-proBNP values were significantly lower in
patients with diastolic dysfunction and diastolic failure when
compared with patients without these disorders. Our results
are similar to the results obtained by Dahlstrom et al in their
study of diastolic heart failure or dysfunction in the elderly.9
Besides the hypothesis postulated by Dahlstorm et al, this
finding may also be attributable to the pitfalls in the
diagnostic criteria for diastolic dysfunction/failure in the
elderly that remains controversial. The European Study
Group on diastolic heart failure requires signs or symptoms
of congestive cardiac failure, normal or only mildly reduced
left ventricular systolic function and abnormal left ventri-
cular relaxation, filling, and diastolic stiffness.10 A single set
of values are applied to subjects aged 50 and above. However,
diastolic parameters change with increasing age11 12 and in
the very elderly, precise parameters required to make the
diagnosis remains unclear. A single set of values for over 50
years of age may not differentiate abnormal dysfunction from
normal ageing.
Obtaining high quality Doppler signals are difficult in the
elderly,13 which makes it even more difficult to diagnose
diastolic dysfunction in this group. It has been suggested that
there is no concordance in diastolic parameters used in the
diagnosis of diastolic dysfunction.14 Presence of atrial
fibrillation makes these parameters even less reliable and
Table 3 Characteristic NT-proBNP (pg/ml) concentrations for patients with and without diastolic dysfunction diastolic
dysfunction with LA enlargement and LVH, and diastolic failure
Diastolic dysfunction Diastolic dysfunction and LAE and LVH Diastolic failure
Yes No Yes No Yes No
Number 26 27 8 45 13 40
Geometric mean 193.2 636.1 190.7 395.9 244.6 399.5
95% CI 115.0 to 324.6 294.3 to 1374.4 105.0 to 346.4 226.7 to 691.2 129.7 to 461.2 216.6 to 736.7
Table 4 Characteristic NT-proBNP concentrations for
patients with and without atrial fibrillation in the absence
of systolic dysfunction and valve heart disease
Atrial fibrillation Yes No
Number 13 40
Geometric mean 1242.5 239.5
95% CI 481.7 to 3434.8 142.2 to 391.2
Table 5 Characteristic NT-proBNP concentrations for
patients with and without valve heart disease in the
absence of systolic dysfunction
Valve heart disease Yes No
Number 22 53
Geometric mean 1205.0 354.6
95% CI 709.9 to 2045.5 219.1 to 573.9
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hence highlighting the difficulties in interpreting abnormal
diastolic values in the elderly. Hence our findings need to be
interpreted in the context of pitfalls in the diagnosis of
diastolic dysfunction.
Our study has proved that NT-proBNP can be used reliably
to exclude significant valve heart disease with negative
predictive values exceeding 90%. Noticeably 28% of patients
referred for echocardiography had normal NT-proBNP values
with good negative predictive values for systolic dysfunction
and significant valve disorders. This has significant implica-
tions for service provision. This may have a role in
rationalising the utility of echocardiography in secondary
care. Confronted with a normal NT proBNP, it is down to the
clinician to weigh the clinical suspicion and the high negative
predictive value while requesting an echocardiogram. In
patients with increased NT-proBNP, raised levels are non-
specific and the need for further investigations such as an
echocardiogram will not be significantly reduced.
There are limitations in this study, including its small
sample size and the small number of patients in each cohort,
which made it difficult to further categorise diastolic
dysfunction. The concentrations of NT proBNP in this study
could have been influenced by renal and thyroid function and
heart rate that were not analysed and correlated as there is
emerging evidence that values of natriuretic peptides are
affected by these variables.
CONCLUSIONS
This study showed that NT-proBNP has excellent negative
predictive value for systolic dysfunction and significant valve
disorders in very elderly patients. It increases significantly in
systolic dysfunction, significant valve heart disease and atrial
fibrillation in patients aged 75 years and over. NT-proBNP is
not useful in the diagnosis of diastolic dysfunction or
diastolic failure using standard echocardiography criteria.
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Table 6 Sensitivity, specificity, and predictive values in valve heart disease for different
cut off values of NT-proBNP
NTproBNP cut off
(pg/ml) Sensitivity Specificity
Positive predictive
value
Negative predictive
value
227 91 43 40 92
334 91 53 44 93
424 82 55 43 88
Key points
N NT-proBNP is a reliable test in ruling out systolic
dysfunction and significant valve disorder in patients
aged 75 and over.
N NT-proBNP is not useful in the diagnosis of diastolic
dysfunction or failure in patients aged 75 and above
using standard echocardiographic criteria.
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